1 - 25 of 37 results for author:"Greenberg N.M." in Literature citations
Results Customize
› Repeat search in UniProtKB (8)
| Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. Chou C.K., Schietinger A., Liggitt H.D., Tan X., Funk S., Freeman G.J., Ratliff T.L., Greenberg N.M., Greenberg P.D. J. Immunol. 189:3936-3946(2012) · Mapped (7) |
| Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Chang G., Xu S., Dhir R., Chandran U., O'Keefe D.S., Greenberg N.M., Gingrich J.R. Clin. Cancer Res. 16:5390-5401(2010) · Mapped (5) |
| Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Schayek H., Seti H., Greenberg N.M., Sun S., Werner H., Plymate S.R. Mol. Cell. Endocrinol. 323:239-245(2010) · Mapped (11) |
| Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Sutherland B.W., Knoblaugh S.E., Kaplan-Lefko P.J., Wang F., Holzenberger M., Greenberg N.M. Cancer Res. 68:3495-3504(2008) · Mapped (4) |
| NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., Knoblaugh S., Cado D., Greenberg N.M., Greenberg N.R. et al. Immunity 28:571-580(2008) · Mapped (9) |
| SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Fasso M., Waitz R., Hou Y., Rim T., Greenberg N.M., Shastri N., Fong L., Allison J.P. Proc. Natl. Acad. Sci. U.S.A. 105:3509-3514(2008) · UniProtKB (1) |
| Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Zhang Y., Zhang J., Lin Y., Lan Y., Lin C., Xuan J.W., Shen M.M., McKeehan W.L., Greenberg N.M., Wang F. Development 135:775-784(2008) · Mapped (45) |
| Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Kaplan-Lefko P.J., Sutherland B.W., Evangelou A.I., Hadsell D.L., Barrios R.J., Foster B.A., Demayo F., Greenberg N.M. Oncogene 27:2868-2876(2008) · Mapped (7) |
| Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Raina K., Blouin M.J., Singh R.P., Majeed N., Deep G., Varghese L., Glode L.M., Greenberg N.M., Hwang D., Cohen P. et al. Cancer Res. 67:11083-11091(2007) · Mapped (4) |
| Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Veiseh M., Gabikian P., Bahrami S.B., Veiseh O., Zhang M., Hackman R.C., Ravanpay A.C., Stroud M.R., Kusuma Y., Hansen S.J. et al. Cancer Res. 67:6882-6888(2007) · Mapped (3) |
| Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Chung A.C., Zhou S., Liao L., Tien J.C., Greenberg N.M., Xu J. Cancer Res. 67:5965-5975(2007) · Mapped (7) |
| Bub1 up-regulation and hyperphosphorylation promote malignant transformation in SV40 tag-induced transgenic mouse models. Guo C., Wu G., Chin J.L., Bauman G., Moussa M., Wang F., Greenberg N.M., Taylor S.S., Xuan J.W. Mol. Cancer Res. 4:957-969(2006) · Mapped (2) |
| Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Chmelar R., Buchanan G., Need E.F., Tilley W., Greenberg N.M. Int. J. Cancer 120:719-733(2007) · Mapped (25) |
| Targeting Aurora kinases for the treatment of prostate cancer. Lee E.C., Frolov A., Li R., Ayala G., Greenberg N.M. Cancer Res. 66:4996-5002(2006) · Mapped (4) |
| Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. Huizen I.V., Wu G., Moussa M., Chin J.L., Fenster A., Lacefield J.C., Sakai H., Greenberg N.M., Xuan J.W. Clin. Cancer Res. 11:7911-7919(2005) · Mapped (2) |
| A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Majeed N., Blouin M.J., Kaplan-Lefko P.J., Barry-Shaw J., Greenberg N.M., Gaudreau P., Bismar T.A., Pollak M. Oncogene 24:4736-4740(2005) · Mapped (6) |
| Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). Mentor-Marcel R., Lamartiniere C.A., Eltoum I.A., Greenberg N.M., Elgavish A. J. Nutr. 135:989-995(2005) · Mapped (11) |
| Conditional deletion of Rb causes early stage prostate cancer. Maddison L.A., Sutherland B.W., Barrios R.J., Greenberg N.M. Cancer Res. 64:6018-6025(2004) · Mapped (7) |
| Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Maddison L.A., Huss W.J., Barrios R.M., Greenberg N.M. Prostate 58:335-344(2004) · Mapped (5) |
| Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Jin C., McKeehan K., Guo W., Jauma S., Ittmann M.M., Foster B., Greenberg N.M., McKeehan W.L., Wang F. Cancer Res. 63:8784-8790(2003) · Mapped (8) |
| Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Kazansky A.V., Spencer D.M., Greenberg N.M. Cancer Res. 63:8757-8762(2003) · Mapped (1) |
| Pten dose dictates cancer progression in the prostate. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T. et al. PLoS Biol. 1:E59-E59(2003) · Mapped (19) |
| Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Freeman K.W., Welm B.E., Gangula R.D., Rosen J.M., Ittmann M., Greenberg N.M., Spencer D.M. Cancer Res. 63:8256-8263(2003) · Mapped (9) |
| Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Freeman K.W., Gangula R.D., Welm B.E., Ozen M., Foster B.A., Rosen J.M., Ittmann M., Greenberg N.M., Spencer D.M. Cancer Res. 63:6237-6243(2003) · Mapped (9) |
| Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Polnaszek N., Kwabi-Addo B., Peterson L.E., Ozen M., Greenberg N.M., Ortega S., Basilico C., Ittmann M. Cancer Res. 63:5754-5760(2003) · Mapped (7) |